Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

uniQure N.V. - Ordinary Shares (NQ:QURE)

22.91 -1.49 (-6.11%)
Streaming Delayed Price Updated: 10:25 AM EST, Feb 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about uniQure N.V. - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
News headline image
FDA Outlines Process To Speed Up Rare Disease Therapy Approvals ↗
FDA launches Rare Disease Evidence Principles to guide therapy reviews, offering new pathways for approval while raising questions on development impact. 
Via Benzinga
News headline image
Vinay Prasad's Comeback To FDA Sparks Debate Over Regulatory Direction ↗
Vinay Prasad returns as FDA's CBER director after brief exit, raising questions on rare disease drug approvals and mRNA vaccine oversight. 
Via Benzinga
News headline image
What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday? ↗
Vinay Prasad exits FDA's biologics division following pressure over Sarepta's Elevidys approval and regulatory controversies. 
Via Benzinga
News headline image
uniQure Narrows Loss in Fiscal Q2 ↗
Via The Motley Fool
News headline image
Earnings Scheduled For July 29, 2025 ↗
 
Via Benzinga
News headline image
uniQure Earnings Preview ↗
 
Via Benzinga
News headline image
Earnings Outlook For uniQure ↗
 
Via Benzinga
News headline image
uniQure NV (NASDAQ:QURE) Posts Q2 2025 Earnings: EPS Beat Offsets Revenue Miss as Regulatory Progress Boosts Shares ↗
uniQure NV reports mixed Q2 2025 results with revenue missing estimates but EPS beating forecasts. Shares rise on regulatory progress for Huntington's gene therapy AMT-130. 
Via Chartmill
News headline image
uniQure Announces Second Quarter 2025 Financial Results and Highlights of Recent Company Progress
From uniQure Inc.
Via GlobeNewswire
News headline image
uniQure to Announce Second Quarter 2025 Financial Results
uniQure to host earnings call on Tuesday, July 29, 2025 at 8:30 a.m. ET 
From uniQure Inc.
Via GlobeNewswire
News headline image
uniQure Announces Appointment of Kylie O’Keefe as Chief Customer and Strategy Officer
From uniQure Inc.
Via GlobeNewswire
News headline image
uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease
From uniQure Inc.
Via GlobeNewswire
News headline image
uniQure Presents Clinical Case Study of First Patient Dosed with AMT-260 in Refractory Mesial Temporal Lobe Epilepsy (MTLE)
From uniQure Inc.
Via GlobeNewswire
News headline image
UniQure Narrows Q1 Loss But Revenue Plummets: Retail’s In Wait-And-Watch Mode ↗
The company narrowed its first-quarter loss to $0.82 per share, down from $1.36 per share in 2024. 
Via Stocktwits
News headline image
uniQure Announces First Quarter 2025 Financial Results and Highlights of Recent Company Progress
From uniQure Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For May 9, 2025 ↗
 
Via Benzinga
News headline image
uniQure to Announce First Quarter 2025 Financial Results
~ uniQure to host inaugural earnings call on Friday, May 9, 2025 at 8:30 a.m. ET ~ 
From uniQure Inc.
Via GlobeNewswire
News headline image
Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost ↗
The new FDA commissioner had a few key ideas for the agency in an interview with Megyn Kelly. 
Via Investor's Business Daily
Topics Government
News headline image
Wolverine World Wide, Pacira BioSciences And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗
Looking for insights into the US markets one hour before the close of the markets on Thursday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
News headline image
Which stocks are moving on Thursday? ↗
Here are the top movers in Thursday's session, showcasing the stocks with significant price changes. 
Via Chartmill
News headline image
uniQure Stock Jumps On FDA’s Breakthrough Therapy Designation For Investigational Gene Therapy: Retail’s Optimistic ↗
The new designation is in addition to the existing Regenerative Medicine Advanced Therapy, Orphan Drug, and Fast Track designations granted to AMT-130. 
Via Stocktwits
Topics Bankruptcy
News headline image
There are notable gap-ups and gap-downs in today's session. ↗
Traders are paying attention to the gapping stocks in Thursday's session. Let's dive into which stocks are experiencing notable gaps. 
Via Chartmill
News headline image
uniQure, Hertz Global, Eli Lilly And Other Big Stocks Moving Higher On Thursday ↗
 
Via Benzinga
News headline image
What's going on in today's pre-market session ↗
Let's have a look at what is happening on the US markets before the opening bell on Thursday. Below you can find the top gainers and losers in today's pre-market session. 
Via Chartmill
News headline image
Why Is Gene Therapy Developer uniQure Stock Trading Higher On Thursday? ↗
uniQure's AMT-130 receives FDA Breakthrough Therapy designation for Huntington's disease, adding to Fast Track, RMAT, and Orphan Drug statuses. 
Via Benzinga
News headline image
uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington’s Disease
From uniQure Inc.
Via GlobeNewswire
News headline image
uniQure Announces 2024 Financial Results and Highlights Recent Company Progress
From uniQure Inc.
Via GlobeNewswire
News headline image
uniQure/ CSL Behring's Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four Years ↗
CSL and uniQure's Hemgenix shows sustained efficacy in hemophilia B, reducing bleeding rates by 90% and eliminating prophylaxis need for most patients at year four. 
Via Benzinga
News headline image
uniQure Announces Completion of Enrollment in the First Cohort and Favorable Recommendation from the Independent Data Monitoring Committee for its Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease
From uniQure Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.